Peptide Aggregation in Biologics

Peptide aggregation represents a critical quality attribute concern in biologics development, with aggregation potentially compromising therapeutic efficacy, altering pharmacokinetics, and provoking immunogenic responses. Understanding aggregation pathways and implementing mitigation strategies are essential for developing safe and effective peptide therapeutics.

Amyloid Formation Pathways

Amyloid aggregation proceeds through nucleation-dependent polymerization, beginning with monomeric peptides adopting partially unfolded conformations that expose hydrophobic residues. Primary nucleation generates amyloid nuclei, which elongate through monomer addition to form protofibrils and mature fibrils. Secondary nucleation processes, including surface-catalyzed events on existing fibrils, accelerate aggregation exponentially once a critical fibril mass accumulates. Kinetic analysis reveals that small molecule inhibitors targeting secondary nucleation can reduce aggregate burden by 90-99% in model systems.

Non-Native Aggregation Mechanisms

Beyond amyloid pathways, peptides form soluble oligomers, amorphous aggregates, and covalent adducts through disulfide scrambling, deamidation, and oxidation. Solution conditions including pH, ionic strength, temperature, and interfacial stress (air-liquid, solid-liquid interfaces) modulate aggregation propensity. Computational tools such as AGGRESCAN and TANGO predict aggregation-prone regions with 70-85% accuracy, guiding rational sequence design to minimize aggregation liability.

Analytical Characterization Methods

Comprehensive aggregation characterization employs orthogonal techniques: size-exclusion chromatography (SEC) for soluble aggregate quantification, dynamic light scattering (DLS) for submicron particle detection, transmission electron microscopy (TEM) and atomic force microscopy (AFM) for morphological analysis, and thioflavin T fluorescence for amyloid fibril detection. Emerging technologies including microflow imaging and nanoparticle tracking analysis provide enhanced sensitivity for subvisible particle characterization at concentrations relevant to clinical dosing.

Formulation Strategies

Aggregation mitigation involves multiple complementary approaches: pH optimization to maximize electrostatic repulsion, surfactant addition (polysorbate 80, poloxamer 188) to minimize interfacial adsorption, tight-binding excipients (cyclodextrins, hydroxypropyl-beta-cyclodextrin) that stabilize native conformations, and lyophilization to reduce solution-phase mobility. Accelerated stability testing at elevated temperatures enables rapid assessment of formulation robustness, with Arrhenius modeling predicting long-term stability from short-term data.